Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer
Cedars-Sinai Medical Center · University of California, Los Angeles · +5 more institutions
Abstract
PURPOSE: This multicenter, open-label, phase II study was undertaken to assess the antitumor activity and safety of the oral mitogen-activated extracellular signal regulated kinase kinase (MEK) inhibitor, CI-1040, in breast cancer, colon cancer, non-small-cell lung cancer (NSCLC), and pancreatic cancer. PATIENTS AND METHODS: Patients with advanced colorectal, NSCLC, breast, or pancreatic cancer received oral CI-1040 continuously at 800 mg bid. All patients had measurable disease at baseline, a performance status of 2 or less, and adequate bone marrow, liver, and renal function. Expression of pERK, pAkt, and Ki-67 was assessed in archived tumor specimens by quantitative immunohistochemistry. RESULTS:…
Citation impact
- FWCI
- 14.58
- Percentile
- 100%
- References
- 11
Authors
15- JJJohn J. RinehartCorresponding
Cedars-Sinai Medical Center, University of California, Los Angeles, University of Alabama at Birmingham, The Barbara Ann Karmanos Cancer Institute, Los Angeles Medical Center, Mayo Clinic in Florida, Oncology Hematology Care
- AAAlex A. Adjei
Cedars-Sinai Medical Center, University of California, Los Angeles, University of Alabama at Birmingham, The Barbara Ann Karmanos Cancer Institute, Los Angeles Medical Center, Mayo Clinic in Florida, Oncology Hematology Care
- PLPatricia LoRusso
Cedars-Sinai Medical Center, University of California, Los Angeles, University of Alabama at Birmingham, The Barbara Ann Karmanos Cancer Institute, Los Angeles Medical Center, Mayo Clinic in Florida, Oncology Hematology Care
- DWDavid Waterhouse
Cedars-Sinai Medical Center, University of California, Los Angeles, University of Alabama at Birmingham, The Barbara Ann Karmanos Cancer Institute, Los Angeles Medical Center, Mayo Clinic in Florida, Oncology Hematology Care
- JRJ. Randolph Hecht
Cedars-Sinai Medical Center, University of California, Los Angeles, University of Alabama at Birmingham, The Barbara Ann Karmanos Cancer Institute, Los Angeles Medical Center, Mayo Clinic in Florida, Oncology Hematology Care
Topics & keywords
- Medicine
- Internal medicine
- Breast cancer
- Pancreatic cancer
- Gastroenterology
- Colorectal cancer
- Nausea
- MEK inhibitor
- Good health and well-being